Skip to main content

Black Diamond Therapeutics, Inc.

BDTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001701541

No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.

Superinvestors holding BDTX, Q2 2026

See all superinvestors

No superinvestor reported holding BDTX in Q2 2026.